Haralabos Kalofonos
University of Patras
H-index: 78
Europe-Greece
Top articles of Haralabos Kalofonos
Incidence and risk factors for developing chemotherapy‐induced neuropathic pain in 500 cancer patients: A file‐based observational study
Journal of the Peripheral Nervous System
2024/2/4
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
Journal of Clinical Oncology
2024/1
Radical Tumor Denervation Activates Potent Local and Global Cancer Treatment
Cancers
2023/7/25
Foteinos-Ioannis Dimitrakopoulos
H-Index: 9
Konstantinos Konstantinidis
H-Index: 0
Haralabos Kalofonos
H-Index: 39
Avelumab first-line maintenance therapy for advanced urothelial carcinoma: comprehensive clinical subgroup analyses from the JAVELIN Bladder 100 phase 3 trial
European Urology
2023/7/1
Howard Gurney
H-Index: 33
Joaquim Bellmunt
H-Index: 72
Haralabos Kalofonos
H-Index: 39
Shilpa Gupta
H-Index: 53
Bo Huang
H-Index: 16
Ras suppressor-1 (RSU1) exerts a tumor suppressive role with prognostic significance in lung adenocarcinoma
Clinical and Experimental Medicine
2023/7
Small Extracellular Vesicles (sEVs) Biogenesis Molecular Players Are Associated with Clinical Outcome of Colorectal Cancer Patients
Cancers
2023/3/9
Abstract P2-26-03: TRAF3 as a regulator of breast cancer aggressiveness
Cancer Research
2023/3/1
Anastasios Papanastasiou
H-Index: 1
Haralabos Kalofonos
H-Index: 39
Molecular epidemiology and treatment patterns of patients with EGFR exon 20-mutant NSCLC in the precision oncology era: the European EXOTIC Registry
JTO clinical and research reports
2023/1/1
Resistance to hormone therapy in breast cancer cells promotes autophagy and EGFR signaling pathway
American Journal of Physiology-Cell Physiology
2023/9/1
Analysis of RANK-c interaction partners identifies TRAF3 as a critical regulator of breast cancer aggressiveness
Neoplasia
2022/11/1
EP10. 01-018 Thromboprophylaxis for Lung Cancer Patients: Results From ACT4CAT Trial
Journal of Thoracic Oncology
2022/9/1
1091P Predictive and prognostic value of Patras Immunotherapy Score (PIOS) in patients with advanced NSCLC treated with immunotherapy/chemotherapy combination
Annals of Oncology
2022/9/1
EP08. 01-072 Clinical Value of Patras Immunotherapy Score (PIOS) Formula in Patients With Advanced NSCLC Treated With Immunotherapy/Chemotherapy
Journal of Thoracic Oncology
2022/9/1
Validation of Patras Immunotherapy Score model for prediction and prognosis of patients with advanced NSCLC treated with nivolumab or pembrolizumab: results from a European …
Therapeutic Advances in Medical Oncology
2022/9
Adhesion strength and anti-tumor agents regulate vinculin of breast cancer cells
Frontiers in Oncology
2022/8/16
Haralabos Kalofonos
H-Index: 39
George Athanassiou
H-Index: 9
Isolated optic neuritis after pembrolizumab administration for non-small-cell lung carcinoma
International Journal of Neuroscience
2022/7/3
Olga E Makri
H-Index: 10
Foteinos-Ioannis Dimitrakopoulos
H-Index: 9
Foteini Tsapardoni
H-Index: 4
Haralabos Kalofonos
H-Index: 39
Prognostic value of PIOS (Patras Immunotherapy Score) model in patients with advanced NSCLC treated with combination of immunotherapy with chemotherapy: Preliminary results …
2022/6/1
Haralabos Kalofonos
H-Index: 39
Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer
2022/6
Howard Gurney
H-Index: 33
Haralabos Kalofonos
H-Index: 39
Joaquim Bellmunt
H-Index: 72
Bo Huang
H-Index: 16
Prospectively assessing serum neurofilament light chain levels as a biomarker of paclitaxel‐induced peripheral neurotoxicity in breast cancer patients
Journal of the Peripheral Nervous System
2022/6
